UBS AG is outlining preliminary trigger callable contingent Yield notes priced at $1,000.00 each and linked to the least-performing of three specified underlyings. Investors face structured-note exposure rather than a bank deposit, with no FDIC or government-agency insurance and secondary-market pricing that may differ from UBS AG’s internal valuation.
Key Highlights
- Maturity is due on or about October 7, 2031, subject to the notes’ terms.
- Each note has a $1,000 public issue price and carries a $2.50 Underwriting discount.
- The notes are not bank deposits and do not carry FDIC or other government-agency insurance.
UBS AG is outlining preliminary trigger callable contingent yield notes with a $1,000 public issue price per note.
$1,000 Notes Carry $2.50 Underwriting Discount
The preliminary pricing supplement is dated September 24, 2026, and the terms remain subject to completion. The securities are not bank deposits and do not carry insurance from the Federal Deposit Insurance Corporation or another government agency. UBS Securities LLC, an affiliate of UBS AG, has a conflict of interest under FINRA Rule 5121 and cannot sell the notes to an account under its discretionary authority without prior specific written approval from the account holder. Prices immediately after issuance may exceed UBS AG’s internal valuation because of underwriting, hedging and issuance costs and projected trading profit, with that difference declining to zero over the stated period.
FAQs
Q: What is the public issue price for each note?
A: The stated public issue price is $1,000 per note.
Q: When is the preliminary pricing supplement dated, and are the terms final?
A: The preliminary pricing supplement is dated September 24, 2026.
Q: Who has the FINRA Rule 5121 conflict, and what selling restriction applies?
A: UBS Securities LLC, an affiliate of UBS AG, has the stated conflict under FINRA Rule 5121. It cannot sell the notes to a discretionary account without prior specific written approval.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.